News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Active Biotech AB Advances ANYARA into Phase III Clinical Trial
May 13, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LUND, SWEDEN--(Marketwire - May 13, 2008) - Lund, Sweden, May 13, 2008 - An interim analysis has been performed in Active Biotech AB's (OMX Nordic: ACTI) ongoing Phase II/III clinical study of ANYARA, in patients with advanced renal cell cancer.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Europe
MORE ON THIS TOPIC
Podcast
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
April 1, 2026
·
1 min read
·
Heather McKenzie
Insights
The Brave New World of Radiotherapeutics
April 1, 2026
·
4 min read
·
Jennifer C. Smith-Parker
Rare diseases
PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting Disease
March 31, 2026
·
2 min read
·
Heather McKenzie
Immunology and inflammation
AAD 2026: Sanofi, Incyte, Roivant and Alumis Make Headway Into Skin Diseases
March 31, 2026
·
4 min read
·
Tristan Manalac
